Fonterra Shareholders' Fund logo

Fonterra completes sale of DFE Pharma

M&A22 January 2020FSFConsumer Staples

23 January 2020

FONTERRA COMPLETES SALE OF DFE PHARMA


Fonterra today announces that it has completed the sale of its 50% share of DFE Pharma to CVC

Strategic Opportunities II.


As previously announced in September 2019, this sale was subject to regulatory approvals from

competition authorities and these have now all been received.


Fonterra CFO, Marc Rivers, says the completion of this sale is a key milestone in strengthening the Co-

op’s balance sheet, with cash proceeds of $554 million, comprising of the original sale proceeds of $537

million plus $17 million in settlement adjustments.


Over the course of the 2020 financial year Fonterra expects there to be other one-off transactions as it

implements strategy and continues its asset portfolio review.


“It is too early to assess the overall impact of these on the Co-op’s 2020 financial year. The announced

forecast earnings range will continue to reflect just the underlying performance of the business. We will

provide details of the overall impact of all one-offs as part of our full-year financial statements and will also

provide an update as part of our Interim Results,” Mr Rivers says.



-ENDS-


For further information contact:


Fonterra Communications

24-hour media line

Phone: +64 21 507 072

Data sourced from publicly available filings. Our datasets may not be complete. Automated analysis can produce errors. If you believe any data on this page is incorrect, please contact us at hello@nzxplorer.co.nz. For informational purposes only. Not investment advice.

Other issuers discussed similar conditions around this time

Matched by meaning across NZX announcement text, not keywords — based on our semantic index of announcement bodies.